Save the date! Join the #MedEd CoP for a virtual networking event on Tues, April 16 at 2pm PT / 5pm ET! Hosted by Sam Brondfield, MedEd CoP Chair. Zoom link coming soon on the ASCO Connection page! Stay tuned! #OncMedEd Sam Brondfield, MD, MAEd Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Lori Rosenstein, MD Liza Henry McDonald

Vol 2 of our MedEd CoP Newsletter just dropped! 📰
Featuring upcoming virtual events, summary of our inaugural MedEd Mentorship Program, and overview of events planned at #ASCO24 ! View it here, or download from the ASCO Connection community page! #oncmeded #meded #Oncology

GI Series: #ColonCancer algorithm, w/ Aparna Raj Parikh to reiterate the current landscape:

Full Discussion:
- cancernetwork.com/treatment-algo…
- Oncbrothers.com/colon-2024
-Also on the “Oncology Brothers” podcast

#OncTwitter CancerNetwork® #MedTwitter #GISM #crcsm

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

🎯🧬🎯🧬Tumor-agnostic treatments:
Beginning of the New Era.....
OncoAlert ASCO ESMO - Eur. Oncology FDA Oncology EU Medicines Agency #PrecisionMedicine Eric Topol

While osimertinib and afatinib are both active in #EGFR G719X mutant NSCLC, report Clinical Cancer Research shows that the E709X co-mutation mediates primary resistance to 3G EGFR TKIs and afatinib may be the better choice when present.

aacrjournals.org/clincancerres/…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

Happy to share our review on adj Tx MIUC (pre-EAU) lot of progress w/ IMvigor010, AMBASSADOR, CM274, PROOF302, POUT trials.
Charbel Hobeika, MD Fuat Bicer MD, PhD Cleveland Clinic MD

Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Eviden... sciencedirect.com/science/articl…

70M- stage 3B melanoma BRAF neg with LN in axilla
Started Nivo & 6 mth developed clinical & rad multiple enlarged LN in same axilla
Getting surgery and mostly Xrt
Systemic therapy ?
Oncology Brothers Sewanti Limaye 🇮🇳🇺🇸 Dr Amol Akhade Santhosh Ambika

‼️ GAME-CHANGING for our patients with limited-stage small cell lung cancer

Phase 3 ADRIATIC study of durvalumab after chemoradiation for patients w/ limited-stage SCLC

✅ OS benefit
✅ PFS benefit

Eager to review the full results OncoAlert #lcsm

#TDxD now U.S. FDA approved for pan-tumor w/ HER2 IHC3+ solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

- Dose 5.4 mg/kg
- Common AE: fatigue,…

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

Fantastic work looking at #tucatinib activity post #TDXd for #HER -2+ #bcsm . These real world looks at a drug's activity when sequencing is altered/new drugs are approved is important!

jamanetwork.com/journals/jaman…

Proud to work with LUNGevity Foundation & team to develop a discussion guide for biomarker testing for patients with solid tumors.

Learn more here: lungevity.org/biomarkerdiscu…

#patienteducation #lcsm

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases : SENOMAC trial

'In clinically node-negative patients with sentinel lymph node biopsy showing macrometastasis (1 or 2), comprehensive ALND can be omitted'

OncoAlert
nejm.org/doi/full/10.10…

Where is RT 👀?

Despite overall dearth of RCTs comparing local modalities in HCC, we have randomized studies in support of RT across the disease spectrum:

Early/Intermediate stage: Loma Linda trial - RT (protons) vs. TACE: similar OS, RT better PFS & local control…

Krishan Jethwa Neil Newman Oncology Brothers In summary:
📌The *only* non-surgical local treatment modality with level I evidence for an OS advantage for PVT is SBRT, which treated tumors up to 20 cm with 5 fractions of ablative SBRT [RTOG 1112].
📌There are three negative RCTs (SARAH, SIRveNIB, SORAMIC), although some may…

This is the #Algorithm we have used during our discussion w/ Tanios Bekaii-Saab, MD for #HCC !

#OncTwitter #MedTwtitter #gism #MedEd CancerNetwork® #OncEd #LiverCancer

GI Series: #HCC algorithm, w/ Tanios Bekaii-Saab, MD to reiterate the current landscape:

Full Discussion:
- cancernetwork.com/treatment-algo…
- Oncbrothers.com/algorithm-HCC-…
-Also on the “Oncology Brothers” podcast
-🗣️ Aparna Raj Parikh & Sam Klempner to follow.

#OncTwitter CancerNetwork® #MedTwitter #GISM